NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902

BMT CTN 1902

NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902

MM CAR-T to Upgrade Response BMT CTN 1902

This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma (MM).

Sponsor

Marcelo Pasquini, MD

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Blood and Marrow Transplant Clinical Trials Network

National Cancer Institute (NCI)

National Marrow Donor Program

Celgene a wholly owned subsidiary of BMS

Information provided by (Responsible Party)

<